Article Text

Download PDFPDF
Adjuvant carboplatin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer
  1. Guler Yavas1,
  2. Cagdas Yavas1,
  3. Erdem Sen2,
  4. Irem Oner2,
  5. Cetin Celik3 and
  6. Ozlem Ata2
  1. 1 Department of Radiation Oncology, Selcuk University, Konya, Turkey
  2. 2 Department of Medical Oncology, Selcuk University, Konya, Turkey
  3. 3 Division of Gynecological Oncology Konya, Department of Gynecology and Obstetrics, Selcuk University, Konya, Turkey
  1. Correspondence to Guler Yavas, Department of Radiation Oncology, Faculty of Medicine, Selcuk University, Konya 42075, Turkey; guler.aydinyavas{at}gmail.com

Abstract

Introduction Standard treatment for locally advanced cervical cancer (LACC) includes concomitant chemoradiotherapy (CRT) that typically controls localized disease. However, most patients develop distant metastasis, ultimately leading to death.

Objective To determine the role of adjuvant carboplatin and paclitaxel for clinical outcomes in patients with LACC.

Methods Between 2010 and 2017, 109 patients with LACC were retrospectively evaluated. All patients received cisplatin (40 mg/m2) with concurrent external-beam radiotherapy (up to 50.4 Gy), followed by intra-cavitary brachytherapy. Forty-six of 109 patients received a median of six cycles (range 3–6 cycles) of adjuvant chemotherapy consisting of paclitaxel (175 mg/m2) and carboplatin (CRT + chemotherapy group; area under the curve 5). The remaining 63 patients did not receive adjuvant chemotherapy (CRT group).

Results Disease-free survival and overall survival after a median follow-up of 24.5 months (range 2.6–94.75 months) were 93.5% and 95.7% and 69.8% and 82.5 % for the CRT + chemotherapy and CRT groups, respectively (p = 0.001, p = 0.012, respectively). No acute grade 3/4 gastrointestinal or genitourinary toxicities were seen during CRT. During adjuvant chemotherapy, the most troublesome side effects were hematologic and neurologic toxicities; however, most were manageable. No chronic grade 3/4 genitourinary toxicities were seen.

Discussion Adjuvant chemotherapy in patients with LACC significantly improved both disease-free survival and overall survival without increasing unmanageable toxicity. Future larger prospective trials are warranted to verify these findings.

  • chemotherapy
  • cervical cancer
  • cisplatin
  • locally advanced
  • radiotherapy
View Full Text

Statistics from Altmetric.com

Footnotes

  • Presented at Accepted as 2018 ASTRO e-poster Presentation.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.